Will GlaxoSmithKline plc, Alliance Pharma plc And Smith & Nephew plc Keep Beating The FTSE 100?

Should you pile into these 3 healthcare stocks right now? GlaxoSmithKline plc (LON: GSK), Alliance Pharma plc (LON: APH) and Smith & Nephew plc (LON: SN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the last month, Alliance Pharma (LSE: APH) has outperformed the FTSE 100 by over 6%. This index-beating performance could continue, with the company today releasing an upbeat set of results that show it’s on track to deliver improved profitability over the medium-to-long term.

Key to this is the integration of the Sinclair Healthcare Products acquisition, which is progressing well. This has contributed to a near-doubling of the business, with Alliance Pharma having extended its reach from 40 countries to over 100 and increased its portfolio to over 90 products. And with the company’s bottom line rising by 8% on an adjusted basis, it has enabled an increase in dividends per share of 10%. With dividends being covered 3.3 times by profit, further rises in shareholder payouts are on the cards and could positively catalyse investor sentiment in Alliance Pharma.

With the company’s shares trading on a price-to-earnings-growth (PEG) ratio of just 1.6, they seem to offer significant upside. And with Alliance Pharma being in a highly transformative period, now could be an opportune moment to buy for the long term.

Defensive stock

Also beating the FTSE 100 in the last month has been GlaxoSmithKline (LSE: GSK). Its shares have risen by 7% during the period versus a flat performance from the FTSE 100, with further outperformance on the cards.

A key reason for this is the potential for improving investor sentiment in response to GlaxoSmithKline’s new strategy. It’s seeking to cut costs and is forecast to increase its bottom line by 13% in the current year and by a further 6% next year. Beyond the next two years, strong growth appears likely since GlaxoSmithKline continues to have a highly diversified product pipeline. And its consumer goods interests provide a degree of stability during what could prove to be an uncertain period for the global economy.

And with GlaxoSmithKline currently yielding 5.4% and being viewed as a defensive stock, its popularity among growth and income-seeking investors looks set to remain high and allow it to continue beating the wider index.

Sound buy

Meanwhile, Smith & Nephew (LSE: SN) remains a relatively consistent stock that could gain favour if recent market volatility continues. In fact, the wound care and surgical devices specialist has delivered rising earnings in each of the last five years and looking ahead to next year, it’s forecast to post a rise in net profit of 12%. This has the potential to positively catalyse investor sentiment in the stock and with Smith & Nephew trading on a PEG ratio of 1.4, there seems to be significant upside potential.

There’s also scope for a rapid rise in dividends in the long run, since Smith & Nephew currently pays out just 37% of profit as a dividend. It has a yield of only 1.9%, but with dividends likely to rise and its earnings on the up, it could prove to be a sound buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of Alliance Pharma and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

If I’d invested £5,000 in a Nasdaq index fund 5 years ago, here’s how much I’d have now

The Nasdaq index keeps hitting new all-time records in 2024, as US tech stocks fly. How much could I have…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

£500 to invest a month? Consider aiming to turn that into a £20,000 passive income like this!

With a regular monthly investment, it's possible to build a large and steady passive income for retirement. Royston Wild explains.

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Investing Articles

As retirement needs soar 60%, here’s how I’m building wealth with UK shares

A regular investment in UK shares and funds could help Brits create a large and lasting pension. Our writer Royston…

Read more »

Investing Articles

I’d buy Games Workshop shares before they reach the FTSE 100!

Games Workshop shares look likely to join the FTSE 100 soon. Here’s why I think investors should consider buying the…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Could me buying this stock with a $2.5bn market-cap be like investing in Tesla in 2010?

Archer Aviation (NASDAQ:ACHR) stock's nearly doubled so far in November. Could this start-up be another Tesla in the making?

Read more »

Investing Articles

5,000 shares of this UK dividend stock could net me £1,700 a month in passive income

Our writer calculates the passive income he could earn from holding a significant number of shares in this powerful dividend-paying…

Read more »

Investing Articles

9.3%+ yields! 3 FTSE 100 dividend giants to consider buying

Our writer examines a trio of high-yield FTSE 100 shares and explains some of the opportunities and risks he sees…

Read more »

Investing Articles

As the Kingfisher share price drops on Budget fallout, should I buy?

The Kingfisher share price was on a strong 2024 run until the DIY group warned us of the possible effects…

Read more »